Stroke outcomes, recovery correlate with MMP-9 levels

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Serum levels of matrix metalloprotease 9 (MMP-9) are associated with stroke outcomes and clinical improvement.

Why this matters

  • MMP-9 levels are known to increase after cerebral ischemia and may modulate complications associated with tissue plasminogen activator (TPA) therapy.

Key results

  • MMP-9 levels at admission were associated with 1-mo outcomes by modified Rankin Scale (mRS) score (P=.001).
  • MMP-9 levels at 1 mo were associated with National Institutes of Health Stroke Scale (NIHSS) score and mRS score at 1 mo (P=.004 and P=.001, respectively).
  • MMR-9 levels at 1 mo were associated with NIHSS score and mRS score at onset (P=.002 and P=.001, respectively).
  • MMP-9 levels at 1 mo were associated with clinical improvement (difference between NIHSS score at onset and 1 mo, P=.022).

Study design

  • 30 patients with acute ischemic stroke and 30 controls patients were analyzed for associations between MMP-9 and stroke severity, outcomes, and clinical recovery.
  • Funding: None disclosed.

Limitations

  • Small patient sample size.